脐带间充质干细胞治疗糖尿病足的研究进展

Progress of umbilical cord mesenchymal stem cell transplantation for the treatment of diabetic foot

全球大约有15%的糖尿病患者有发展成为足溃疡的可能,其中6%需要住院治疗。糖尿病足(DF)的治疗已成为威胁人类健康的世界性公共卫生问题,需要更为有效的治疗方案。脐带间充质干细胞(UCMSCs)是具有自我复制和多向分化潜能的原始细胞,可通过改善糖尿病下肢缺血、修复糖尿病周围神经病变(DPN)及调节免疫等方面促进足部创面愈合,且Wnt/β-catenin信号通路在治疗中发挥重要的调节作用。UCMSCs治疗已成为治疗糖尿病及其并发症的一种有潜力的治疗新方法,具有广阔的应用前景。

Patients with diabetes have about 15% lifetime risk of developing a foot ulcer worldwide,and 6- of which need hospitalized treatment. So far, treatment of diabetic foot （DF） remains one of the burning issues for health care in diabetic populations and the DF treatment still deemed dismal and unsatisfactory, more effective treatment strategies are warranted. Umbilical cord mesenchymal stem cells（UCMSCs）are progenitor cells which, have the ability of self-renewal and multilineage differentiation. It can promote the foot wound healing through the improvement of diabetic lower limb isehemia, repair diabetes peripheral neuropathy and immune regulation. The Wnt/β-catenin signaling pathway plays an important regulatory role in UCMSC transplantation treatment. The UCMSC transplantation has become a novel cell therapeutic protocol for the treatment of diabetes mellitus and its complications. It has a broad application prospect.